| 标题： | 无导线心脏起搏器植入术操作流程及规范 |
| title： | Leadless Pacemaker:Operation Procedure and Standard |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 标准指南 |
| classification： | Standard guideline |
| 领域： | 诊疗 |
| field： | Diagnosis and Treatment |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 医师 |
| Guide users： | Physicians |
| 证据分级方法： | 推荐：良好的科学证据提示该医疗行为带来的获益实质性地压倒其潜在的风险。临床医生应当对适用的患者告讨论该医疗行为； *应该考虑：至少是尚可的证据提示该医疗行为带来的获益超过其潜在的风险。临床医生应对适用的患者讨论该医疗行为； * 可以考虑：至少是尚可的科学证据提示该医疗行为能提供益处，但获益与风险十分接近，无法进行一般性推荐。临床医生不需要提供此医疗行为，除非存在某些个体性考虑； * 不推荐：至少是尚可的科学证据提示该医疗行为的潜在风险超过潜在获益；临床医生不应该向无症状的患者常规实施该医疗行为； |
| Evidence grading method： | Recommendated: Good scientific evidence suggests that the benefits of the medical practice substantially outweigh the potential risks. Clinicians should discuss the medical practice with indicated patient reports; *Should be considered: At least fair evidence that the benefits of the medical practice outweigh the potential risks. Clinicians should discuss the medical practice with indicated patients; * May be considered: At least fair scientific evidence suggests that the medical practice provides benefits, but the benefits are too close to the risks to make a general recommendation. Clinicians are not required to provide this medical practice unless certain individual considerations exist; * Not recommended: At least fair scientific evidence suggests that the potential risks of this medical practice outweigh the potential benefits; clinicians should not routinely perform this medical practice on asymptomatic patients; |
| 制定单位： | 中国医师协会心律学专业委员会， 中华医学会心电生理和起搏分会 |
| Formulating unit： | Chinese Society of Arrthymia, China Society of Pacing and Electrophysiology |
| 注册时间： | 2022-06-18 |
| Registration time： | |
| 注册编号： | IPGRP-2022CN350 |
| Registration number： | |
| 指南制订的目的： | 起搏器是心动过缓患者的主要治疗手段。传统起搏器由于电极和囊袋，因此存在与之相关的并发症。无导线起搏器经静脉直接植入在心腔，无电极和皮下囊袋，大大降低了并发症发生率。由于无导线起搏器的植入方法和患者管理与传统起搏器有较大不同个，因此中国医师协会心律学专业委员会， 中华医学会心电生理和起搏分会组织撰写了无导线起搏器的操作流程及规范，让这项疗法能够更加规范有序的推广 |
| Purpose of the guideline： | "The pacemaker is the only effective treatment for bradyarrhythmias, and the leadless pacemaker is a milestone change and progress in the history of cardiac pacing therapy. It has accumulated a lot of experience in various aspects in the process of clinical promotion and popularization. The CSA and CSPE jointly advocated and organized the writing of this expert consensus, aiming to standardize the clinical application of this new technology and make this technology safer and can carry out orderly in China Pacemakers are the mainstream treatment for patients with bradycardia. Conventional transvensous pacemaker may lead to complications due to the leads and pockets. The leadless pacemaker is directly implanted into the heart via veins. Without lead and subcutaneous pockets, it will greatly reduce the incidence of complications. Because the implantation procedure and patient management of leadless pacemakers are quite different from those of traditional pacemakers, The CSA and CSPE jointly organized and wrote the standard operating procedures and starndard aiming to standardize the clinical application of this new technology." |
最新注册
